GWM
RYTM icon

Geneos Wealth Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Geneos Wealth Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-44
Closed -$2.31K – 2952
2024
Q3 		$2.31K Buy
+44
New +$2.11K ﹤0.01% 2266
2021
Q4 		– Sell
-200
Closed -$2K – 2860
2021
Q3 		$2K Hold
200
– – ﹤0.01% 2666
2021
Q2 		$4K Hold
200
– – ﹤0.01% 2528
2021
Q1 		$4K Hold
200
– – ﹤0.01% 2740
2020
Q4 		$4K Hold
200
– – ﹤0.01% 2556
2020
Q3 		$4K Buy
+200
New +$4.58K ﹤0.01% 2273

Other funds holding RYTM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geneos Wealth Management's RYTM Position: Q4 2024 in Review

Geneos Wealth Management sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2024, closing a stake of 44 shares — an estimated $2.31K sold.

Geneos Wealth Management first reported a position in RYTM in Q3 2020 and held it in 6 quarters. The position peaked at $4K in Q2 2021. 203 funds tracked by Wall St. Rank hold RYTM as of Q4 2024.

  • Geneos Wealth Management reported no remaining Rhythm Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Geneos Wealth Management sold 44 Rhythm Pharmaceuticals shares in Q4 2024, an estimated $2.31K.
  • Geneos Wealth Management first reported a position in Rhythm Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • Geneos Wealth Management's Rhythm Pharmaceuticals position peaked at $4K in Q2 2021.
  • 203 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2024.

Based on Geneos Wealth Management's 13F filing for Q4 2024, filed 21 Jan 2025.